360 Index Name Paper ref. Name Paper ref. Perez-Vizcaino, F Tue 121, Mon 374, Wed 226, Thu 217 Pergolizzi, S Thu 316 Perhariè, L Wed 153 Peric, M Thu 324, Wed 103 Perju-Dumbrava, L Tue 481 Perkecz, A Tue 271 Perna, A Thu 014 Pernas, S Mon 146 Pernomian, L Thu 236 Perreau, V Mon 045 Perretti, M FC09.5.7, FC09.4.6 Perrin-Sarrado, C Wed 244 Perroy, J FC11.3.3 Perry, M FC06.1.1 Pertz, HH W13.4 Peshavariya, H Mon 194, FC06.4.5, Wed 219, FC15.2.5 Pesic, S Thu 070 Pesquero, JB Thu 061, Wed 041 Petcu, LC Mon 162 Petermann, O Wed 108 Peters, D YI.10 Peters, JA Tue 479, FC03.3.5 Peters, J Tue 049 Peters, S Thu 258, Thu 082 Petersen, CN Mon 154 Petersen, KB FC07.4.5 Petersen, L J W26.3 Petersen, LG Mon 345 Petersen, M FC13.3.6, Mon 119, Mon 118, Mon 406 Petersen, MS Wed 151 Peterson, C Tue 395 Peterson, S Wed 423 Pethö, G Tue 078 Pétrault, O Thu 237 Petrella, C Tue 249, Petridis, I Mon 187 Petroni, RC Wed 204 Petronijevic, M Tue 367 Petronijevic, N Wed 343 Petrovic, B Thu 436, Mon 446 Petrovic, V Tue 050 Petrrault, O FC17.2.5 Petrushun, V Wed 122, Wed 121, Wed 120 Petsalo, A Mon 063 Pexa, K Wed 022 Peyronel, C Tue 289, Tue 290 Peytavin, G Tue 040 Pfeifer, A Tue 129 Pfister, M FC07.3.2 Pfleger, KDG Wed 079 Phadungrakwittaya, R Thu 335 Philippu, A W33.1 Phillips, M Wed 123 Phillips, O Tue 340 Piacente, S Tue 406 Picchianti, L Wed 442, Mon 382 Piccione, F Tue 405, Wed 010 Pichette, V W06.4 Pichini, S Mon 375 Pichkhadze, G Thu 336 Tue 079 Piekorz, R Wed 022 Pieles, U Tue 134 Pieratti, A Wed 317 Pierse, N Tue 136 Pietro, B Thu 400 Pietrobon, D FC12.1.4 Pietsch, J Thu 267, Wed 252 Pignier, C Tue 170, Tue 171, Tue 172 Pihlaja, T Mon 063 Pilar-Cuellar, F Wed 401 Pilar-Cuillar, F Thu 408 Pilatova, M Tue 423 Pilegaard, H Wed 281 Pillai, K Wed 419 Pillai, KK Tue 137, Piltonen, M Mon 447 Pimentel, F Tue 086 Pin, J-P FC11.2.1, FC11.3.5, FC11.3.6, Wed 077, Thu 035, Thu 083 Ping, J Tue 130 Pinheiro, H Tue 123 Pinheiro, R Mon 298 Pinho, MJ Mon 057 Pintér, E W19.3, Mon 318, Tue 271, Tue 250 Pinto, R Tue 207 Pipelzadeh, MH Tue 251 Piperski, V Wed 343 Piqueras, L Thu 437 Piquette-Miller, M W06.2, Tue 050 Piras, V Tue 133 Pirkmajer, S Tue 048 Pirmohamed, M FC13.3.4 Pirovano, M Thu 111 Pirro, E Tue 405, Wed 010 Pistritto, G Mon 281 Pitre, S Mon 166 Pitre, Shweta Tue 131 Pitterle, K Wed 148 Pitychoutis, P W33.4 Piwnica, D Thu 088 Pizza, C Tue 406 Pizza, V Tue 487, Mon 448, Tue 488, Mon 449 Pizzolatti, MG Wed 394 Plante, I Tue 051 Plath, N FC17.4.2 Platzer, W FC11.1.6 Plenge, P FC02.3.5 Plevin, R Tue 252 Pliskova, M Tue 222 Pochetti, G Thu 433 Pochop, P Tue 445 Podestá, MHMC Tue 101, Mon 010 Podracka, L Thu 033 Pogantsch, M Mon 153 Pogge, T PL08 Pohanka, M Tue 343, Mon 075, Tue 074, Tue 448 Pohjanoksa, K Wed 092 Pohjolainen, V Tue 166 Poitou, C FC01.4.4 Pokorná, P Wed 017, Mon 267 Pol, O Thu 042, Wed 059
Name Paper ref. Name Paper ref. Polaskova, A Tue 342 Pold, R Tue 132 Polenzani, L Thu 433 Polewicz, D FC06.3.6 Polónia, J Thu 119 Pols, T FC18.2.4 Ponce, L Tue 394 Ponciano, E Mon 350 Pongnarin, P Tue 007, Mon 357, Mon 355, Mon 334 Pons, G FC10.1.1 Poopyruchpong, N Tue 277 Pope, HG FC14.5.1 Popova, O Mon 462 Popovici, ED Tue 102 Popovici, MG Tue 102 Popp, R Mon 417, Mon 438, Tue 481 Porreca, F FC03.2.1 Pórszász, R Tue 125 Porter, E Wed 269, Wed 238 Porto, LC Wed 342 Postnikov, PV Wed 175 Poston, R Thu 197 Potschka, H FC02.2.3 Potter, CMF Thu 241, Thu 238 Poulsen, A Thu 106 Poulsen, FM Tue 053 Poulsen, H Mon 118 Poulsen, HE FC04.2.4, Mon 345, Tue 480, Tue 482, Mon 119 Poulsen, M Tue 080 Poulsen, P Mon 406 Pourcel, L Mon 129 Pourmotabbed, A Mon 437 Poutanen, M Wed 446 Pouton, C Thu 280 Povarnina, P Mon 225 Povlsen, GK Mon 450, Thu 239 Powell, C Mon 393, Mon 420 Poyner, D Wed 057 Pozgai, G Thu 197 Pozsgai, G Tue 271 Pradelli, L Mon 223 Pradelli, L Wed 154 Praliev, K Tue 079 Prasad, AN FC10.2.5 Prasad, R Mon 028 Prat, I Tue 394 Pratt, J FC17.1.4 Preininger, A FC11.3.2 Preston, K FC14.3.4 Preston, R Wed 155 Prezeau, L FC11.2.1 Pribula, J Wed 090 Priestley, J Thu 278 Prieto, D FC08.2.5, Thu 249, Mon 239, Tue 213, Mon 411 Prieto, E Tue 103 Prilutsky, A Tue 057 Prinsen, J Wed 156 Prinzis, S Tue 133 Pritchard, D Mon 282 Procaccini, C Wed 393, Thu 409 Procházka, V Tue 475 Proctor-Brown, C Tue 372 Proksch, B YI.02 Prosser, R Thu 019 Prostran-Veselinovic, M Tue 013, Mon 114, Wed 009, Tue 026, W34.1, W34.2 Prudhomme, M Tue 429 Prunier, C Thu 055 Prusa, R Tue 137 Ptacek, LJ FC12.4.4 Ptak-Belowska, A Tue 463 Pubill, D Wed 177, Wed 174, Thu 179, Wed 181 Puerta-Vazquez, R Wed 349 Pugi, A Thu 302, Pugnet, G Tue 104 Puppala, B Wed 184 Pupure, J Mon 429, Tue 253, Wed 045 Pursley, J Tue 495 Putter, S Tue 110 Puttonen, KA W21.3 Putula, J Thu 051 Pyo, H-B Thu 385 Pyriochou, A FC15.3.6 Qi, C Mon 032, Thu 410 Qi, H Thu 368 Qi, T Wed 057 Qian, G Mon 031 Qian, J Thu 089 Qiang, G Thu 384 Qiang, GF Mon 433 Qin, H Thu 372 Qin, H-L Wed 346 Qin, Y Thu 295 Qiu, H FC02.1.5 Qu, H Tue 173, Tue 325 Qu, HJ Mon 008 Quadros, I FC14.4.3 Que, A Tue 158 Queckenberg, C Thu 010 Queiroz, E Wed 375 Queiroz, MGR Wed 297 Quick, M FC02.1.2 Quignard, J-F Wed 293 Quinn, J Tue 271 Quinn, JP W19.3 Quinn, TJ FC15.1.6 Quiroz, G Thu 187 Ra, R Thu 051 Raasmaja, A Mon 341 Rabello, MM Thu 374 Racca, S Tue 405 Racek-Król, B Mon 181 Radacic-Aumiler, M Tue 328, Mon 135 Radhakrishnan, AK Tue 254 Radojicic, R Tue 122 Radonjic, N Wed 343 Radovic, J FC16.3.6 Radovic, V Wed 157 Radwanska, A Mon 197 Ragia, G Mon 187 Rägo, L FC01.4.3 Rahbar, A Tue 014 Rahbari, S Wed 301 Rahimi, A Wed 364 Index 361
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor